Baird Starts Coherus Biosciences (CHRS) at Outperform
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Baird initiates coverage on Coherus Biosciences (NASDAQ: CHRS) with a Outperform rating and a price target of $40.00.
Analyst Michael Ulz commented, "We view Coherus as a potential leader in the biosimilar space with an experienced management team and differentiated legal strategy. Coherus boasts a robust late-stage biosimilar pipeline, including CHS-1701 (Neulasta biosimilar) under regulatory review, CHS-1420 (Humira biosimilar) in Phase 3, and CHS-0214 (Enbrel biosimilar) filing early next year in Europe. We expect numerous meaningful catalysts ahead to drive further upside, culminating in the launch of its first biosimilar product in 2018."
Shares of Coherus Biosciences closed at $28.88 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Oppenheimer Starts Fortive (FTV) at Perform
- Neurocrine Bio. (NBIX) PT Lowered to $56 at Jefferies Amid Adult Tourette's Data
- Deutsche Bank Cuts Price Target on Neurocrine Biosciences (NBIX) Following Study
Create E-mail Alert Related CategoriesAnalyst Comments, New Coverage
Related EntitiesRobert W Baird, S1
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!